Skip to the page

Data / Federal grants / PAR-25-070

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

National Institutes of Health (Department of Health and Human Services) is accepting applications until January 7, 2027.

SpecStream is the live web data engine for teams and agents. It reads every open and forecast federal opportunity on Grants.gov each morning, and this page is that reading. Describe your organization once and the grants that fit arrive in your sheet, CRM, Slack or agent as they are posted.

Key facts

Opportunity number
PAR-25-070
Status
Posted, open
Posted
November 18, 2024
Closes
January 7, 2027
Cost sharing
Not required
Funding instrument
Grant
Category
Education, Health
Assistance listing
93.393 Cancer Cause and Prevention Research; None None
Contact
National Institutes of Health · [email protected] · 301-402-2541

Who can apply

  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Public and State controlled institutions of higher education
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Small businesses
  • County governments
  • For profit organizations other than small businesses
  • State governments
  • City or township governments
  • Public housing authorities/Indian housing authorities
  • Special district governments
  • Independent school districts
  • Private institutions of higher education

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

What the agency says

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

The notice on Grants.gov Full announcement

Other open grants from the Department of Health and Human Services

All grants open to Nonprofits without 501(c)(3) status · All grants open to Public colleges and universities · All grants open to Nonprofits (501(c)(3)) · Everything closing in January 2027

Read from the Grants.gov API, last updated 2026-10-23. The agency's notice on Grants.gov is the official record; check it before you apply.